Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 909Carboplatin 786Paclitaxel 741pembrolizumab 741Bevacizumab 715Cisplatin 707Gemcitabine 621Docetaxel 583Rituximab 558Radiotherapy 546Dexamethasone 510Nivolumab 488Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 357Pemetrexed 336Oxaliplatin 335Cytarabine 334Lenalidomide 327Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 315Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 275

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Comparative Genomic Hybridization × Clear all
NCT01336933 2023-09-22

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

University of Nebraska

Phase 2 Completed
34 enrolled 12 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡